Quick Answer
Nuo Therapeutics, Inc. reported Operating Income Loss of -$2.52 million for the year ending 2025.
- Nuo Therapeutics, Inc. showed a decrease of -2.4% in Operating Income Loss from 2024 to 2025.
- This data is from Nuo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2010 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: -$2.72 million | Q2 2012: -$2.35 million | Q3 2012: -$4.21 million | Q1 2013: -$5.00 million | Q2 2013: -$4.66 million | Q3 2013: -$4.61 million | Q1 2014: -$4.65 million | Q2 2014: -$9.82 million | Q3 2014: -$4.50 million | Q1 2015: -$3.37 million | Q2 2015: -$4.44 million | Q3 2015: -$27.26 million | Q1 2016: -$1.97 million | Q2 2016: -$1.11 million | Q3 2016: -$1.86 million | Q1 2017: -$1.68 million | Q2 2017: -$3.91 million | Q3 2017: -$1.38 million | Q1 2018: -$667.7 thousand | Q2 2018: -$582.7 thousand | Q3 2018: -$411.8 thousand | Q1 2019: -$611.8 thousand | Q2 2019: -$392.4 thousand | Q3 2019: -$38.7 thousand | Q1 2020: -$42.4 thousand | Q2 2020: -$5.8 thousand | Q3 2020: -$6.3 thousand | Q1 2021: -$5.7 thousand | Q2 2021: -$6.5 thousand | Q3 2021: -$6.8 thousand | Q1 2022: -$521.8 thousand | Q2 2022: -$923.7 thousand | Q3 2022: -$911.9 thousand | Q1 2023: -$855.2 thousand | Q2 2023: -$871.4 thousand | Q3 2023: -$789.6 thousand | Q1 2024: -$709.2 thousand | Q2 2024: -$542.0 thousand | Q3 2024: -$577.4 thousand | Q1 2025: -$745.1 thousand | Q2 2025: -$652.0 thousand | Q3 2025: -$540.1 thousand.
- Over the full 15 years of available data (2010 to 2025), Nuo Therapeutics, Inc.'s Operating Income Loss has grown by 53.4%.
- Historical annual values: Fiscal year 2025: -$2.52 million | Fiscal year 2024: -$2.46 million | Fiscal year 2023: -$3.17 million | Fiscal year 2022: -$3.32 million | Fiscal year 2021: -$90.7 thousand | Fiscal year 2020: -$378.1 thousand | Fiscal year 2019: -$969.2 thousand | Fiscal year 2018: -$1.50 million | Fiscal year 2017: -$15.53 million | Fiscal year 2015: -$41.32 million | Fiscal year 2014: -$23.39 million | Fiscal year 2013: -$18.10 million | Fiscal year 2012: -$12.89 million | Fiscal year 2011: -$3.51 million | Fiscal year 2010: -$5.40 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: